Titan Pharmaceuticals Reports First Quarter 2016 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Titan Pharmaceuticals Reports First Quarter 2016 Financial Results

SOUTH SAN FRANCISCO, CA--(Marketwired - May 10, 2016) - Titan Pharmaceuticals, Inc. ( NASDAQ : TTNP ), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery platform, today reported financial results for the first quarter ended March 31, 2016.

Titan reported no license revenue for the first quarter of 2016, compared with approximately $0.9 million for the comparable period in 2015. License revenue in the first quarter of 2015 reflected the amortization of the upfront license fee received from commercialization and development partner Braeburn Pharmaceuticals in December 2012.

Total operating expenses, consisting of research and development expenses (R&D) and general and administrative (G&A) expenses, were approximately $1.8 million in the first quarter of 2016, compared with approximately $2.5 million in the first quarter of 2015. R&D expenses for the quarter ended March 31, 2016 were approximately $0.7 million, compared with approximately $1.4 million for the same period in 2015. While there were increases during the first quarter of 2016 in external research and development expenses related to the support of our Probuphine® and ProNeura product development programs, employee-related expenses and other R&D expenses, these were offset by the reimbursement by Braeburn of expenses associated with Probuphine. During the first quarter of 2016, external R&D expenses related to Titan's product development programs were approximately $0.6 million, compared with approximately $0.4 million for the same quarter in 2015.

G&A expenses for the quarters ended March 31, 2016 and 2015 remained consistent at approximately $1.1 million. Net other expenses for the first quarter of 2016 were approximately $15,000 compared with approximately $3.3 million for the same period in 2015. Net other expenses consisted primarily of non-cash gains and losses on changes in the fair value of warrants, tax expenses, and interest income. Net loss for the quarter ended March 31, 2016 was approximately $1.8 million, or approximately $0.09 per share, compared with approximately $4.9 million, or approximately $0.24 per share, in the same quarter in 2015.

At March 31, 2016 Titan had cash of approximately $5.8 million, which the company believes is sufficient to fund operations through the end of 2016. This does not include the milestone payment of $15 million that we will receive upon the approval of Probuphine.

"The recommendation by U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee (PDAC) in January to approve Probuphine marked yet another important step in our efforts to bring this valuable long-term maintenance treatment to those suffering from opioid addiction," said Titan CEO and President Sunil Bhonsle. "While we await the completion of FDA's review of our new drug application (NDA) for Probuphine later this month, we continue to advance our other development programs based on ProNeura. We are proceeding with the required non-clinical studies to support the potential submission of an investigational new drug (IND) application for our ropinirole implant for Parkinson's disease by the end of the year, and continuing the non-clinical development work for a ProNeura-based T-3 implant to treat hypothyroidism."

Marc Rubin, M.D., executive chairman of Titan, added, "We are excited about the potential commercialization of Probuphine, which, if approved, would be Titan's first product on the market based on our ProNeura long-term, continuous drug delivery platform. Our proprietary ProNeura technology has potential for the treatment of other select chronic diseases, and as we expand our product pipeline, significant potential for our company in the coming years."

Business highlights include:

  • In January, the FDA convened a meeting of the PDAC to review the NDA for Probuphine submitted in August 2015. Following presentations and a discussion of the information, the committee voted 12 to 5 in favor of approval of Probuphine. In February the FDA extended its action date by three months to May 27, 2016 citing the changes submitted to the Risk Evaluation and Mitigation Strategy (REMS) section of the NDA as a major amendment requiring additional time to complete its review.
  • In late January, Titan received written feedback from the FDA on the initial development plan for its proprietary ropinirole hydrochloride (HCL) implant for Parkinson's disease. Based on the FDA's feedback on the development plan submitted in December 2015, Titan is proceeding with the required non-clinical studies to support the potential submission of an IND application in the fourth quarter of 2016, followed by the initial pharmacokinetic and proof-of-concept clinical study. Titan is pursuing a 505(b)(2) registration pathway for the product candidate.
  • In April, Titan presented data from the last Phase 3 trial of Probuphine at the 47th Annual American Society of Addiction Medicine (ASAM) Annual Conference . The data indicates that participants who were clinically stable on sublingual buprenorphine at a dose of 8mg or less per day maintained stability when transferred to Probuphine, and that they were more likely to sustain abstinence from illicit opioids throughout the six months than participants who remained on sublingual buprenorphine.

Conference Call Titan management will host a live conference call at 1:15 p.m. PT / 4:15 p.m. ET on Tuesday, May 10, 2016 to discuss the company's financial results as of March 31, 2016. The call will be hosted by Sunil Bhonsle, president and CEO; Kate Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance; and Marc Rubin, M.D., executive chairman.

The live webcast of the call may be accessed by visiting the Titan website at www.titanpharm.com . The call can also be accessed by dialing 800-279-9534 , participant passcode 6051842, five minutes prior to the start time. A replay of the call will be available on the company website approximately two hours after completion of the call and will be archived for two weeks.

About Titan Pharmaceuticals Titan Pharmaceuticals Inc. ( NASDAQ : TTNP ), based in South San Francisco, CA, is a specialty pharmaceutical company developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company's lead product candidate is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Probuphine employs Titan's proprietary drug delivery system ProNeura™, which is capable of delivering sustained, consistent levels of medication for three months or longer. Titan has granted North American commercial rights for Probuphine to Braeburn Pharmaceuticals. If approved, Probuphine would be the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology has the potential to be used in developing products for treating other chronic conditions such as Parkinson's disease, where maintaining consistent blood levels of a dopamine agonist may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com .

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

 
 
TITAN PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except per share amount)
(unaudited)
    Three Months Ended March 31,
    2016   2015
Revenue:                
  License revenue   $ -     $ 911  
    Total revenue     -       911  
                 
Operating expense:                
  Research and development     700       1,431  
  General and administrative     1,131       1,095  
    Total operating expense     1,831       2,526  
Loss from operations     (1,831 )     (1,615 )
                 
    Other Expense, net     (15 )     (3,282 )
                 
Net loss and comprehensive loss   $ (1,846 )   $ (4,897 )
                 
Basic net loss per share   $ (0.09 )   $ (0.24 )
                 
Diluted net loss per share   $ (0.09 )   $ (0.24 )
                 
Weighted average shares used in computing                
basic net loss per share     20,060       20,031  
                 
Weighted average shares used in computing                
diluted net loss per share     20,400       20,056  
                 
CONDENSED BALANCE SHEETS  
(in thousands)  
(unaudited)  
                 
      March 31,       December 31,  
      2016       2015  
                 
Assets                
  Cash   $ 5,762     $ 7,857  
  Receivables     4,857       4,213  
  Prepaid expenses and other current assets     370       174  
    Total current assets     10,989       12,244  
  Furniture and equipment, net     1,007       1,043  
    Total assets   $ 11,996     $ 13,287  
Liabilities and Stockholders' Equity                
  Current liabilities   $ 5,080     $ 4,853  
  Warrant liabilities     1,440       1,444  
  Stockholders' equity     5,476       6,990  
    Total liabilities and stockholders' equity   $ 11,996     $ 13,287  
                     
                     

Contact: Titan Pharmaceuticals, Inc. Sunil Bhonsle President (650)-244-4990 Investors: Stephen Kilmer (650) 989-2215 skilmer@titanpharm.com Media: Susan Thomas (650) 989-2216 sthomas@titanpharm.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 150

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Home Energy Tips: Embrace the Electrical Panel Shift

Updated Category News Views 75

Why Electrical Panels Matter More Than Ever Back in the day, electrical panels weren't exactly the star of the homeowner show. But times have changed, and those previously mundane boxes of switches and wires now demand a spotlight. Shifts in modern lifestyles have catapulted electrical systems into the spotlight, making upgrades a pressing conversation topic for savvy...

Continue Reading
Rakuten Medical Fires Up Phase 1 Trial for RM-0256 Therapy

Updated Category News Views 203

Taking Aim at Refractory Tumors in Japan Get this—Rakuten Medical is stepping into the ring with their new cancer-busting tactic, RM-0256 photoimmunotherapy, right in Japan. We're talking about a Phase 1 trial that'll throw a new kind of punch at solid tumors, specifically targeting troublesome skin cancers that don’t seem to play nice with current treatments. Now,...

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 113

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
Austin Rattler Event Revamps With Two-Day Off-Road Bash

Updated Category News Views 25

Austin's Off-Road Bash Kicks Up Dust in Hill Country It's not just another grind in the biking and running world; the Life Time Austin Rattler's gone off the reservation pushing the pedals and the pace across the rugged terrain of Texas Hill Country. Here's to muscles burning and soles slapping the dirt for two straight days, all in the name of challenging nature's best....

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 97

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 158

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
Surgical Tooth Extraction: When It’s Necessary

Updated Category News Views 144

Unpacking the Complexities of Tooth Extraction Ever wonder why some tooth extractions are a stroll in the park while others dive straight into surgical territory? It's all about positioning, condition, and what's lurking underneath. Thanks to Dr. Yadira Cardona-Rohena of Hamilton Mill Oral & Facial Surgery, we’ve got the lowdown. The Need for Skilled Surgical Techniques...

Continue Reading
NEDHSA Amplifies Tobacco-Free Push with 2026 Smokeout

Updated Category News Views 73

2026 Great American Smokeout: A Fresh Push Against Tobacco NEDHSA is sticking to its guns with a tobacco-free campaign that’s got deep roots. The 2026 Great American Smokeout, on November 19, not only highlights past efforts but looks to stir more folks into healthier habits. Beyond the campaign glitz, it’s about dragging a century-long bad habit further into the...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 85

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Daily NAVs of WisdomTree ETFs

Updated Category News Views 110

Daily Net Asset Values of WisdomTree ETFs In the dynamic world of exchange-traded funds (ETFs), keeping track of daily Net Asset Values (NAVs) is crucial for investors looking to understand fund performance. WisdomTree Issuer plc has been a significant player in the ETF arena, offering various products that cater to diverse investment strategies. Each ETF represents a...

Continue Reading
How E-commerce Optimization Services Can Improve SEO Rankings

Updated Category Business Views 736

In the digital world, e-commerce companies flourish by being seen and recognized online. As competition grows fiercer, it becomes essential for e-commerce companies to distinguish themselves from competitors. E-commerce optimization services can boost rankings on search engines. Learning how to use e-commerce optimization strategies can help your business achieve business...

Continue Reading
Upcoming Financial Results Announcement by United Maritime

Updated Category News Views 191

Upcoming Financial Results Announcement by United Maritime GLYFADA, Greece — United Maritime Corporation (NASDAQ: USEA) is set to unveil its financial results for the first quarter ending on March 31. The announcement will be made before the market opens in New York on Thursday. Company Overview United Maritime Corporation is recognized as an international shipping...

Continue Reading
Texas Takes Legal Action Against Biden Over Lizard Protection

Updated Category News Views 91

Texas Attorney General Takes on Endangered Species Status In a noteworthy legal move, Texas Attorney General Ken Paxton has launched a lawsuit against the Biden administration over the recent endangered classification of the dunes sagebrush lizard. This designation, made by the U.S. Fish and Wildlife Service, has drawn significant criticism from Paxton, who contends that...

Continue Reading
Kevin T. Carter Takes the Helm as TCMA's Executive VP

Updated Category News Views 215

TCMA Welcomes a New Leader Trade Center Management Associates, LLC (TCMA, A Drew Company), has recently elevated Kevin T. Carter to the position of Executive Vice President. With a remarkable 45 years in the hospitality industry, Carter's extensive knowledge will guide the company’s strategic initiatives, ensuring robust operational leadership and exciting business...

Continue Reading